相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Past, present and future perspectives in nonalcoholic fatty liver disease
Arun J. Sanyal
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
New dual peroxisome proliferator activated receptor agonistSaroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Upendra Kaul et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH
Joost Boeckmans et al.
PHARMACOLOGICAL RESEARCH (2019)
Recent Advances in Body-on-a-Chip Systems
Jong Hwan Sung et al.
ANALYTICAL CHEMISTRY (2019)
The role of the microbiome in NAFLD and NASH
Aleksandra A. Kolodziejczyk et al.
EMBO MOLECULAR MEDICINE (2019)
Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka
Madunil Anuk Niriella et al.
HEPATOLOGY INTERNATIONAL (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
Zobair M. Younossi et al.
TRANSPLANTATION (2019)
The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD
Brandon J. Perumpail et al.
DISEASES (2019)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al.
HEPATOLOGY (2018)
Dual PPAR/agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Mukul R. Jain et al.
LIVER INTERNATIONAL (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
Montserrat A. de la Rosa Rodriguez et al.
BMC GENOMICS (2018)
The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View
Christina C. Lindenmeyer et al.
CLINICS IN LIVER DISEASE (2018)
Organ/body-on-a-chip based on microfluidic technology for drug discovery
Hiroshi Kimura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2018)
PPAR Agonists and Metabolic Syndrome: An Established Role?
Margherita Botta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
PPAR beta/delta: A Key Therapeutic Target in Metabolic Disorders
Xavier Palomer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Nahum Mendez-Sanchez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
Shun Ishibashi et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2018)
Preclinical models of non-alcoholic fatty liver disease
Prasanna K. Santhekadur et al.
JOURNAL OF HEPATOLOGY (2018)
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Thomas Jensen et al.
JOURNAL OF HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Hepatic regulation of VLDL receptor by PPAR beta/delta and FGF21 modulates non-alcoholic fatty liver disease
Mohammad Zarei et al.
MOLECULAR METABOLISM (2018)
A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis
Maddalena Parafati et al.
DISEASE MODELS & MECHANISMS (2018)
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
Fan Hong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease
Xilin Li et al.
TOXICOLOGY (2018)
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
James J. Connolly et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2018)
Drug-induced steatohepatitis
Ajit Dash et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study
Marcin Krawczyk et al.
JOURNAL OF LIPID RESEARCH (2017)
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
Barbara Gross et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Response to: Comment to EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2017)
Targeting the gut-liver axis in liver disease
Reiner Wiest et al.
JOURNAL OF HEPATOLOGY (2017)
Therapies in non-alcoholic steatohepatitis (NASH)
Abdul M. Oseini et al.
LIVER INTERNATIONAL (2017)
Targeting nuclear receptors for the treatment of fatty liver disease
Naoki Tanaka et al.
PHARMACOLOGY & THERAPEUTICS (2017)
A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response
Alison Iroz et al.
CELL REPORTS (2017)
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
Yasushi Honda et al.
SCIENTIFIC REPORTS (2017)
The Selective Peroxisome Proliferator-Activated Receptor-Delta Agonist Seladelpar Reverses Nonalcoholic Steatohepatitis Pathology by Abrogating Lipotoxicity in Diabetic Obese Mice
Fahrettin Haczeyni et al.
HEPATOLOGY COMMUNICATIONS (2017)
The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis
Guillaume Wettstein et al.
HEPATOLOGY COMMUNICATIONS (2017)
Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease
J. Pang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
PPARs and nonalcoholic fatty liver disease
Kim H. H. Liss et al.
BIOCHIMIE (2017)
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Francis W. B. Sanders et al.
BIOLOGICAL REVIEWS (2016)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
Manel Pladevall et al.
BMC CARDIOVASCULAR DISORDERS (2016)
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Aleksander Skardal et al.
DRUG DISCOVERY TODAY (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Hepatic-specific PPARα-FGF21 action in NAFLD
Elena Piccinin et al.
GUT (2016)
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Elena Buzzetti et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Pioglitazone use and risk of bladder cancer: population based cohort study
Marco Tuccori et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Pioglitazone use and risk of bladder cancer: population based cohort study
Marco Tuccori et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
Xiaomeng Feng et al.
MEDICAL SCIENCE MONITOR (2016)
A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout
Jeffrey Poiley et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Non-alcoholic fatty liver and the gut microbiota
Stavros Bashiardes et al.
MOLECULAR METABOLISM (2016)
Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode
Davide Capelli et al.
SCIENTIFIC REPORTS (2016)
Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD
Rosa Lombardi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Ryan E. Feaver et al.
JCI INSIGHT (2016)
Pathogenesis and novel treatment options for non-alcoholic steatohepatitis
Vincent Wai-Sun Wong et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study
V. W. -S. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study
Sun Hwa Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Guillaume Lassailly et al.
GASTROENTEROLOGY (2015)
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
Sven Francque et al.
JOURNAL OF HEPATOLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Inflammasome activation and function in liver disease
Gyongyi Szabo et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
Hong-Mei Yan et al.
PLOS ONE (2015)
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2
Quentin M. Anstee et al.
SEMINARS IN LIVER DISEASE (2015)
Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
Aravind Sosale et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
Gut microbiome and nonalcoholic fatty liver diseases
Lixin Zhu et al.
PEDIATRIC RESEARCH (2015)
Chimeric Mice with Hepatocyte-humanized Liver as an Appropriate Model to Study Human Peroxisome Proliferator-activated Receptor-α
Chise Tateno et al.
TOXICOLOGIC PATHOLOGY (2015)
Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease
Liang Xu et al.
BIOMOLECULES (2015)
EPIDEMIOLOGY AND NATURAL HISTORY OF NAFLD
Claudia Della Corte et al.
JOURNAL OF MEDICAL BIOCHEMISTRY (2015)
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects
Remy Hanf et al.
DIABETES & VASCULAR DISEASE RESEARCH (2014)
The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
Wajahat Zafar Mehal
DIGESTIVE DISEASES (2014)
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells
Alexandra Rogue et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling Pathway
Ning Zhang et al.
ONCOTARGET (2014)
Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease
Vettickattuparambil George Giby et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Zeynel Abidin Ozturk et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Paola Dongiovanni et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Morphological and microarray analyses of human hepatocytes from xenogeneic host livers
Chise Tateno et al.
LABORATORY INVESTIGATION (2013)
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Yun-Jung Choi et al.
ATHEROSCLEROSIS (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress POTENTIAL ROLE IN FRUCTOSE-DEPENDENT AND -INDEPENDENT FATTY LIVER
Miguel A. Lanaspa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
High Rates of Fructose Malabsorption Are Associated with Reduced Liver Fat in Obese African Americans
Ryan W. Walker et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2012)
PPARs: Fatty acid sensors controlling metabolism
Lars la Cour Poulsen et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2012)
Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity
Esther M. M. Ooi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
Harold E. Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis
Suzanne E. Mahady et al.
JOURNAL OF HEPATOLOGY (2011)
Development of Novel Combination Therapies
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Glitazones for human nonalcoholic steatohepatitis
Raluca Pais et al.
Therapeutic Advances in Gastroenterology (2011)
Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome
Mark J. Dekker et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
P. Dongiovanni et al.
GUT (2010)
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis
Shaoqing He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Endogenous Ligands for Nuclear Receptors: Digging Deeper
Michael Schupp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Down-regulation of SREBP-1c is associated with the development of burned-out NASH
Tadanobu Nagaya et al.
JOURNAL OF HEPATOLOGY (2010)
The role of the gut microbiota in nonalcoholic fatty liver disease
Ahmed Abu-Shanab et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation
Anne Bugge et al.
PPAR RESEARCH (2010)
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Maryam Rakhshandehroo et al.
PPAR RESEARCH (2010)
The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 β in the Pathogenesis of Fructose-Induced Insulin Resistance
Yoshio Nagai et al.
CELL METABOLISM (2009)
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
Cindy J. Rubin et al.
DIABETES & VASCULAR DISEASE RESEARCH (2009)
A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans
A. Kotronen et al.
DIABETOLOGIA (2009)
Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease
Luca Miele et al.
HEPATOLOGY (2009)
Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice
Maaike H. Oosterveer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The role of PPAR alpha in lipid metabolism and obesity: Focusing on the effects of estrogen on PPAR alpha actions
Michung Yoon
PHARMACOLOGICAL RESEARCH (2009)
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
C. Fernandez-Miranda et al.
DIGESTIVE AND LIVER DISEASE (2008)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha
Qian Yang et al.
TOXICOLOGICAL SCIENCES (2008)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
PPARs and molecular mechanisms of transrepression
Mercedes Ricote et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
PPARγ in human and mouse physiology
Sami Heikkinen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Modulation of PPAR activity via phosphorylation
Katherine A. Burns et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Impairment of hepatic STAT-3 activation and reduction of PPARα activity in fructose-fed rats
Nuria Roglans et al.
HEPATOLOGY (2007)
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
Catherine Fievet et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
The gut flora as a forgotten organ
Ann M. O'Hara et al.
EMBO REPORTS (2006)
Peroxisome proliferator-activated receptor-α and liver cancer:: where do we stand?
JM Peters et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
An overview on biological mechanisms of PPARs
BP Kota et al.
PHARMACOLOGICAL RESEARCH (2005)
Role of peroxisome proliferator -: Activated receptor-γ in the glucose-sensing apparatus of liver and β-cells
H Kim et al.
DIABETES (2004)
A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis
Arun J. Sanyal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults
HJ Kim et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
分享论文
